We create bacterial therapies of the human skin and mucosal microbiome against pathogenic bacteria. Our first suite of products (NASOFLORE line) targets Staphyloccocus aureus / MRSA (Methicillin resistant S aureus). The products based on live bacteria identified in our clinical and in vitro studies do not generate emergence of antibiotic resistance.